Podcasts about Lancet

Barry Krakow, MD is a board-certified internist and sleep medicine specialist, internationally recognized for the discovery and implementation of the most advanced approaches to solving the disabling sleep problems experienced in mental illness. His new book, Life Saving Sleep: New Horizons in Mental Health Treatment opens up a revolutionary system for treating mental health disorders by targeting the underlying sleep dysfunction. His work appears in leading scientific journals such as The Lancet, JAMA and the American Journal of Psychiatry. His TEDx talk on insomnia has gained three-quarters of a million views and is the most popular discourse by a practicing clinical sleep medicine specialist. In the past 20 years, he has been interviewed or appeared on hundreds of media outlets, including feature presentations on ABC 20/20 and ABC Prime Time as well as featured works in Time Magazine and The New Yorker.His fifth book on sleep tackles the complex array of disorders, particularly nightmares, insomnia and sleep apnea that frequently fall under the radar of most practicing mental health professionals. Sleaping into the breach where the mental health community continually falls short with its robotic reliance on psychotherapy or prescription pad, Dr. Krakow's ground-breaking discoveries offer numerous, advanced psychological and physiological non-drug treatments to heal and often cure sleep problems in those afflicted with mental illness.Dr. Krakow's sleep quest introduced him personally to every form of sleep treatment (except sleeping pills); and, in this journey he discovered, learned, and tested each of these therapies that he now uses with all his patients and clients. For 30 years, he has interacted with mental health professionals to teach and show them how sleep disorders' treatment improves and sometimes cures mental illness. Dr. Krakow is currently the Sleep Medicine Director of the Gateway Behavior Health Psychiatry Residency Training program in Savannah, GA, the first ever sleep training curriculum to directly teach new psychiatrists how to treat sleep disorders without medication.Unfortunately, this cutting edge work remains largely under the radar among many types of healthcare professionals including psychologists and therapists. In a nutshell, far too much energy pushes the myth that counting sleep, if not sheep, is the be-all, end-all, instead addressing the crucial role of physiological sleep quality. Live Saving Sleep proves indisputably that sleep quality trumps sleep quantity.Dr. Krakow is an articulate, engaging, and humorous speaker with a gift for conversation that he applies regularly in caring for his troubled and oft-times desperate patients. Making connections is the key to patient care, and Dr. Krakow will connect to your audience with riveting stories where lives were transformed by proper treatment for the sleep disorders they suffered from for decades. And, he will supply the facts and how-to information to help your audience gain confidence in addressing their own or their family or friends' sleep problems. No one will be put to sleep by this encounter…until the head hits the pillow.www.barrykrakowmd.comfastasleep.substack.com

Generating scientific evidence is, although essential, just the first step. For clinical practice to be driven by evidence we must ensure that the knowledge is translated into policies that guide practice and are available for all. But how? The road from research to clinics is not a linear one, nor it is the same in every setting. Trials conducted in high-income countries can offer limited support to practice-changing in other contexts. So how do we go from evidence to implementation? Taissa Vila, Editor-in-Chief at The Lancet Regional Health - Americas, speaks with Ana Claudia de Souza, a stroke neurologist and trialist at Hospital Moinhos de Vento in Brazil about translating evidence to clinical practice in low- and middle-income settings.You can see all of our Spotlight content relating to research for health here:https://www.thelancet.com/lancet-200/research-for-health?dgcid=buzzsprout_tlv_podcast_lancet200_rfhFind out more about how The Lancet is marking its 200th anniversary with a series of important spotlights here:https://www.thelancet.com/lancet-200?dgcid=buzzsprout_tlv_podcast_lancet200_rfhContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-345 Overview: In this episode, we discuss the findings of a recent Lancet publication on a novel neurokinin 3 (NK3) receptor antagonist for treating hot flashes. Tune in as we talk about how this nonhormonal treatment addresses menopausal hot flashes, the prescribing precautions issued by the FDA, and the implications for patients seeking your help with alleviating symptoms. Episode resource links: Lancet 2023; 401: 1091–102. doi.org/10.1016/ S0140-6736(23)00085-5 Am Fam Physician. 2023;108(1):28-39 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Richard Onorato

Dr. Dickson leads the discussion with recent cases involving the PECARN pediatric head injury decision rule and some super sneaky toxicology. There is some high-level detective work happening during this episode. Listen so you don't miss vital clues in your clinical practice. REFERENCES 1. Kuppermann N, Holmes JF, Dayan PS, et al; Pediatric Emergency Care Applied Research Network (PECARN). Identification of children at very low risk of clinically-important brain injuries after head trauma: a prospective cohort study. Lancet. 2009 Oct 3;374(9696):1160-70. 2. https://www.mchd-tx.org/wp-content/uploads/2023/09/Sodium-Channel-Blocker-Before-1.pdf 3. https://www.mchd-tx.org/wp-content/uploads/2023/09/Sodium-Channel-Blocker-After-2.pdf

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-345 Overview: In this episode, we discuss the findings of a recent Lancet publication on a novel neurokinin 3 (NK3) receptor antagonist for treating hot flashes. Tune in as we talk about how this nonhormonal treatment addresses menopausal hot flashes, the prescribing precautions issued by the FDA, and the implications for patients seeking your help with alleviating symptoms. Episode resource links: Lancet 2023; 401: 1091–102. doi.org/10.1016/ S0140-6736(23)00085-5 Am Fam Physician. 2023;108(1):28-39 Guest: Robert A. Baldor MD, FAAFP   Music Credit: Richard Onorato

Dr. Christopher Makarewich from University of Utah and the Salt Lake City Shriners Hospital returns to the show to discuss his recent research on guided growth in achondroplasia. The lightning round delves deeper into achondroplasia including medical treatment and elective limb lengthening. Your hosts are Josh Holt from University of Iowa, Carter Clement from Children's Hospital of New Orleans, and Julia Sanders from Children's Hospital Colorado. Music by A. A. Aalto.   Citations   Hemiepiphysiodesis for Lower Extremity Coronal Plane Angular Correction in the Distal Femur and Proximal Tibia in Children with Achondroplasia. Makarewich et al. JPO Sept 2023.   Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Savarirayan et al. Lancet 2020.   What's New in Limb Lengthening and Deformity Correction? Bafor and Iobst. JBJS Aug 2023.   Achondroplasia and limb lengthening: Results in a UK cohort and review of the literature. Donaldson et al. Journal of Orthopaedics 2015.   Extensive Limb Lengthening for Achondroplasia and Hypochondroplasia. Paley. Children 2021.

Alongside tackling global warming, conservation and protecting the diversity of our natural world is a global priority.  AI plays a huge role, from analysing satellite imagery of reforestation efforts to identifying wildlife from acoustic scanners or trip cameras. However, there's an issue in these biomes where many people live - these efforts are taking place without their permission. Privacy, data protection and individual rights can potentially be sidelined in the quest for a tech-driven solution to a global problem.Joining us today is Joycelyn Longdon. She's a PhD Student in the Department of Computer Science at Cambridge University. Her research is around looking at the technical, AI-based solutions to environmental protection, and respect local populations, whilst trying to protect our natural habitats. She also runs Climate in Colour, an organisation dedicated to making conversations around climate more diverse and accessible.This is Technology Now, a weekly show from Hewlett Packard Enterprise. Every week we look at a story that's been making headlines, take a look at the technology behind it, and explain why it matters to organisations and what we can learn from it.We'd love to hear your one-minute review of books which have changed your year! Simply record them on your smart device or computer and upload them using this Google form: https://forms.gle/pqsWwFwQtdGCKqED6Do you have a question for the expert? Ask it here using this Google form: https://forms.gle/8vzFNnPa94awARHMAAbout this week's Guest, Joycelyn Longdon: https://www.cst.cam.ac.uk/people/jl2182Climate in Colour: https://climateincolour.com/ 2021: Longdon, J. 2020. “Environmental Data Justice.” The Lancet 4 (November). DOI:10.1016/S2542-5196(20)30254-0.Technology Untangled Season 4 Episode 1 - Unconscious Bias: Is AI dividing us? https://link.chtbl.com/TechnologyUntangled_401Global competition for a limited pool of technology workers is heating up: https://www.imf.org/en/Publications/fandd/issues/2019/03/global-competition-for-technology-workers-costa

The comprehensive geriatric assessment is one of the cornerstones of geriatrics.  But does the geriatric assessment do anything?  Does it improve outcomes that patients, caregivers, and clinicians care about? Evidence has been mounting about the importance of the geriatric assessment for older adults with cancer, the subject of today's podcast.  The geriatric assessment has been shown in two landmark studies (Lancet and JAMA Oncology) to reduce high grade toxicity, improve patient and caregiver satisfaction, and improve completion of advance directives (can listen to our prior podcast on this issue here).  Based on this surge in evidence, the American Society of Clinical Oncologists recently updated their guidelines for care of older adults to state that all older adults receiving systemic therapy (including chemo, immuno, targeted, hormonal therapy) should receive geriatric assessment guided care.  We talk about these new guidelines today with William Dale, a geriatrician at City of Hope and lead author of the guideline update in the Journal of Clinical Oncology, Mazie Tsang, palliative care/heme/onc physician-researcher at Mayo Clinic Arizona who authored a study of geriatric and palliative conditions in older adults with poor prognosis cancers published in JAGS, and John Simmons, a retired heme/onc doctor, cancer survivor, and patient advocate.  We talk about: What is a practical geriatric assessment and how can busy oncologists actually do one? (hint: 80% can be done in advance by patients or caregivers) Why is it that some oncologists are resistant to conducting a geriatric assessment, yet have no problem ordering tests that cost thousands of dollars? What can you do with the results of a geriatric assessment? How does the geriatric assessment lead to improved completion of advance directives, when the assessment doesn't address advance care planning/directives at all? How does palliative care fit into all this?  Precision medicine? What groups are being left out of trials? What are the incentives to get oncologists and health systems to adopt the geriatric assessment?   And Mazie, who is from Hawaii, requested the song Hawaii Aloha in honor of the victims of the wildfire disaster on Maui.  You can donate to the Hawaii Red Cross here. Aloha, -@AlexSmithMD   Additional Links: Brief ASCO Video of how to conduct a practical geriatrics assessment Brief ASCO Video of how to use the results of a practical geriatrics assessment Time to stop saying the geriatric assessment is too time consuming    

Gavin and Jessamy return to the studio for a special chat marking 100 episodes, and are joined by Richard Horton to look back across the last few years of global health and COVID, and discuss the changing landscape of health.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

這次跟大家討論如何在評估過程中運用CFT 以及如何在治療中融入CFT 希望對大家有幫助囉 歡迎到Facebook, Instagram追蹤或來信來訊跟我們提出疑問～ Email: 2propt@gmail.com Timecode: 00:30 閒聊美國的夏令營，跳脫舒適圈 09:40 複習CFT三個重點 12:12 CFT評估流程：是否有紅旗=》是否為慢行？=〉是否為持續性疼痛？=》是否對疼痛、動作有恐懼？=〉判斷疼痛機制（mechanical, nonmechanical, or mix) 18:30 CFT評估流程：判斷可調控的心理因子：認知、情緒 21:30 CFT 評估流程：判斷可調控的行為因子：動作行為、社交行為、生活型態 25:40 CFT處理流程：疼痛教育 30:17 CFT處理流程：可控範圍下動作行為暴露 37:46 CFT處理流程：生活型態改變 42:36 本篇病人處理流程實例 也可以在此收聽： Apple podcast: https://tinyurl.com/y97q7tms Spotify: https://tinyurl.com/ydavzqxu Google podcast: https://tinyurl.com/yd86pbcl YouTube channel: https://tinyurl.com/y82ewo5b Music by Elizabeth's Groove by Amarià @amariamusique Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: bit.ly/elizabeths-groove Music promoted by Audio Library youtu.be/-MO-mrBlo5s Reference: Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial [published correction appears in Lancet. 2023 Jun 17;401(10393):2040]. Lancet. 2023;401(10391):1866-1877. Caneiro JP, Smith A, Rabey M, Moseley GL, O'Sullivan P. Process of Change in Pain-Related Fear: Clinical Insights From a Single Case Report of Persistent Back Pain Managed With Cognitive Functional Therapy. J Orthop Sports Phys Ther. 2017;47(9):637-651.

Dr. Nayantara Coelho-Prabhu, Mayo Clinic gastroenterologist specializing in the care of patients with gastrointestinal bleeding and endoscopy, talks through many aspects of acute GI bleeding. She helps to clarify the prioritization of medications, when to incorporate imaging, broadens our differentials for upper and lower GI bleeding, gives mindblowing advice on stool guiac testing and SO much more in this over-stuffed (or should we say constipated) chapter of Always on EM. There is also a special cameo from Dr. Luke Wood going over how to insert a Minnesota tube (esophageal balloon tamponade device)!   CONTACTS X - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch Email - AlwaysOnEM@gmail.com   RECOMMENDATION: Dieulafoy lesion video from New England Journal of Medicine: https://youtu.be/tzJQDen1nug?si=zOmywZ1VN3VvA004    REFERENCES: Drescher MJ, Stapleton S, Britstone Z, Fried J, Smally AJ. A call for reconsideration of the use of fecal occult blood testing in emergency medicine. Journal of Emerg Med. 2020. 58(1)54-58 Mathews BK, Ratcliffe T, Sehgal R, Abraham JM, Monash B. Fecal Occult Blood testing in hospitalized patients with upper gastrointestinal bleeding. Journal of Hospital Medicine. 2017. 12(7)567-569 Harewood GC, McConnell JP, Harrington JJ, Mahoney DW, Ahlquist DA. Detection of occult upper gastrointestinal bleeding: performance in fecal occult blood tests. Mayo Clin Proc. 2002 Jan;77(1):23-28 Blatchford O, et al. A risk score to predict need for treatment for upper gastrointestinal haemorrhage. Lancet 2000. Oct 14;356(9238):1318-21 Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of scotland: case ascertainment study. BMJ 1997. Aug 30;315(7107):510-4 Chen IC, Hung MS, Chiu TF, Chen JC, Hsiao CT. Risk scoring systems to predict need for clinical intervention for patients with nonvariceal upper gastrointestinal tract bleeding. Am J Emerg Med. 2007 Sep;25(7):774-9 Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol. 2021 May 1;116(5):899-917 Roberts I, Shakur-STill H, Afolabi A, et al. Effects of High-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet 2020. 395(10241):1927-1936 Aziz M, Haghbin H, Gangwani MK, Weissman S, Patel AR, Randhawa MK, Samikanu LB, Alyousif ZA, Lee-Smith W, Kamal F, Nawras A, Howden CW. Erythromycin improves the quality of esophagogastroduodenoscopy in upper gastrointestinal bleeding: a network meta-analysis. Dig Dis Sci 2023. Apr;68(4):1435-1446 Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol 2022;00:1-17 Vigano GL, Mannucci PM, Lattuada A, Harris A, Remuzzi G. Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. Am J Hematol 1989. May;31(1):32-5 Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FL, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010. Sep 8;2010(9):CD002907 Gao Y, Qian B, Zhang X, Liu H, Han T. Prophylactic antibiotics on patients with cirrhosis and upper gastrointestinal bleeding: A meta-analysis. PLoS One 2022. Dec 22;17(12):e0279496 Steffen R, Knapp J, Hanggi M, Iten M. Use of the REBOA catheter for uncontrollable upper gastrointestinal bleeding with hemorrhagic shock. Anaesthesiologie 2023. May;72(5):332-337 Sato M, Kuriyama A. Countering hemorrhagic shock due to duodenal variceal rupture with resuscitative endovascular balloon occlusion of the aorta. Am J Emerg Med 2023. Feb;64:204.e1-204.e3

My guest this week is Matt Zemon, editor of the excellent new book Psychedelics for Everyone: A Beginner's Guide to These Powerful Medicines for Anxiety, Depression, Addiction, PTSD, and Expanding Consciousness (affiliate link). Matt also contributed several chapters to this book. This conversation is a great introduction to the world of psychedelics, and Matt is an excellent guide. He's knowledgeable, compassionate, and he presents a balanced view of the potential place of psychedelics in our lives. Topics we discussed included: What Matt means by “psychedelics for everyone” means The positive effects of psychedelics on a wide range of psychiatric conditions, especially those involving repetitive mental patterns Breaking old patterns of brain activity and creating new ones How psychedelics might have their powerful and lasting positive effects Effects of psychedelics in the spiritual domain Some of my guest's spiritual experiences with psychedelics Different reasons that people approach psychedelic experimentation and use, including medical, spiritual, and libertarian Navigating the legal restrictions on psychedelic use Psychedelic churches Possible adverse effects of taking psychedelics David Nutt's study on risk of harm from different psychoactive substances (create a free account with Lancet to view the full article) The possible role of fear and anxiety on reactions to psychedelics The side effects of psychedelics vs. those of existing prescription medications Paying attention to source, set, and setting People who should definitely not take a psychedelic substance SpiritPharmacist.com for medical consults and to discuss potential psychedelic use Matt Zemon, MSc, is a dedicated explorer of the inner world, and a passionate advocate for the thoughtful and responsible use of psychedelics. With a Master of Science in Psychology and Neuroscience of Mental Health with honors from King's College London, Matt has studied the effects of psychedelics on the mind and the potential for these experiences to serve as a catalyst for positive transformations. His work in this field is motivated by a profound desire to help people navigate the sometimes challenging terrain of the psychedelic experience, and emerge from it with a deeper sense of purpose, connection, and understanding—to reclaim their true self. As an entrepreneur in the wellbeing sector, Matt has co-founded various companies, including: HAPPŸŸ, a mental wellness company specializing in psychedelic-assisted ketamine therapy PSYCHABLE, an online community connecting people who would like to explore the healing power of psychedelics with a network of practitioners and psychedelic-based treatments TAKE2MINUTES, a nonprofit dedicated to helping individuals improve their mental health and wellbeing. For more information visit his website, find him on LinkedIn or Instagram, or contact Matt with your questions. You can order his excellent journal for psychedelic preparation and integration here: Beyond the Trip (affiliate link).

Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, ​​a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with debilitating diseases. Robert and Fady discuss how they have developed a company culture that embraces some of the learnings that come along with failure and the advice they would provide other leaders. They talk about how the current capital market environment shapes the way the company is operating. They also discuss the cardiovascular market and overall landscape, where Cytokinetics is from a development perspective, and some upcoming milestones. Finally, they each share a piece of advice they wish they could provide to their younger selves knowing what they now know. Biography: Robert Blum has served as President and Chief Executive Officer of Cytokinetics and a member of our Board of Directors since 2007. Previously, he served as Cytokinetics' President and held other senior-level positions at the Company overseeing research and development, finance, corporate development, legal, commercial operations, and business development at various times since participating in the launch of Company operations in 1998. Prior to Cytokinetics, Robert held senior positions in business development and marketing at COR Therapeutics from 1991 to 1998. He also performed roles of increasing responsibility in sales, marketing, and other pharmaceutical business functions at Marion Laboratories and Syntex Corporation beginning in 1981. Robert previously served on the faculty at the Center for BioEntrepreneurship at University of California, San Francisco, where he taught a corporate finance course to graduate students. He co-chaired the BIO Business Development Committee and is a frequent lecturer on matters of business development and finance in the biopharmaceutical industry. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Fady Malik has led Research and Development since 2014 and been with Cytokinetics since its inception in 1998 when he joined its founders to participate in the launch of the company. Early on, Fady recognized the potential therapeutic utility of modulating the sarcomere of cardiac and skeletal muscle and led discovery and development efforts giving rise to Cytokinetics' current portfolio of early- to late-stage development programs targeting muscle contractility for the treatment of cardiovascular and neuromuscular diseases. Fady is an internationally recognized cardiovascular physician-scientist, an inventor on more than 20 issued patents, and has authored or co-authored over 60 publications appearing in prominent journals such as Science, Nature Medicine, the Lancet, and the New England Journal of Medicine. He currently holds an appointment in the Cardiology Division of the University of California, San Francisco, as a Clinical Professor of Medicine and until 2019 was an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers. Fady serves on the Board of Directors for Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT). Fady received a B.S. in bioengineering from the University of California at Berkeley, and a M.D./Ph.D. from the University of California at San Francisco where he also completed an internal medicine residency and fellowship in cardiology.

Links: Go to episode page (with resources for this episode) Subscribe to PREMIUM Join the Sigma email newsletter Learn more about Sigma Nutrition Radio About this Episode: One of the most important and influential papers in nutrition science is one by Ancel Keys and his colleagues that was published in The Lancet in 1957. This seminal paper examined the relationship between dietary fat intake and serum cholesterol levels. The researchers investigated how different types of fats in the diet affected cholesterol levels in a series of their previous tightly-controlled dietary experiments.. Those studies involved feeding the participants various diets with different compositions of fats. The researchers analyzed the participants' blood samples to measure changes in serum cholesterol levels in response to dietary changes. The most important aspect of this paper is the presentation of the ‘Keys Equation'; a predictive equation for the impacts of saturated, monounsaturated, and polyunsaturated fats, and dietary cholesterol, on blood cholesterol levels. Crucially, the Keys Equation identifies the importance of the ratio of polyunsaturated to saturated fats in the diet; known as the ‘P:S ratio'. It showed that the P:S ratio is the most important dietary factor impacting blood cholesterol levels. And specifically that saturated fats increase total and LDL cholesterol twice as much as polyunsaturated fats lower them. The findings of this study were significant in highlighting the potential impact of dietary fat subtypes on serum cholesterol levels and heart disease risk. It contributed to the growing body of evidence supporting the hypothesis that high serum cholesterol levels, particularly due to a diet rich in saturated fats, were associated with an increased risk of cardiovascular diseases. In this episode, as part of our new series taking an in-depth look at seminal nutrition studies, we go through this influential paper from Keys, Anderson and Grande.

…sleep restriction for insomnia? A lot of great talks are coming up for Skepticamp at QED in September – with András, Pontus and Claire among the speakers! In TWISH we hear about an almost 200 year old fake news about the moon and then we take a look at the news: UK: Asparagus fails to predict the future SCOTLAND: Loch Ness might be ‘home to spirit entity' that can be disturbed by search UK: Meghan Markle wears ‘miracle antistress patch' INTERNATIONAL: WHO promotes alternative medicine (again!) INTERNATIONAL: Where skeptics go wrong Medical journal the Lancet gets this week Award for being Really Wrong a new article about insomnia. Word of the Week is the Danish word vrøvl. Enjoy! Segments: Intro; Greetings; TWISH; News; Really Wrong; Word Of The Week; Quote And Farewell; Outro; Out-Takes

One way to help ward off dementia is to make sure your hearing is as good as possible. Frank R. Lin is director of the Cochlear Center for Hearing and Public Health, Johns Hopkins Bloomberg School of Public Health and professor of otolaryngology, head and neck surgery. He joins Krys Boyd to discuss why we shouldn't brush off hearing loss as a symptom of old age and the connection between good hearing and cognitive health. His study “Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA” was published in The Lancet.

這次跟大家討論接受及承諾療法ACT和CFT的差異 以及如何幫助病人找到目標 希望大家對CFT有更深一層的了解 Timecode: 00:30 閒聊美國信用卡優惠 11:30 接受與承諾療法ACT與認知功能療法CFT的不同之處 15:34 ACT的六重點：present movement, value, committed action, self as context, cognitive defusion, acceptance 16:00 如何幫助病人找出有意義的治療目標 25:30 不要把注意力放在「疼痛」上 28:55 CFT的評估治療有別於其他心理治療不同之處：問診的重點、衛教解釋疼痛、控制下暴露、生活型態改變 35:30 CFT治療重點複習 36:30 CFT 使用前的注意事項 37:40 認知、情緒相關介入的使用時機，痛三個月就算慢性疼痛嗎？大腦到底發生什麼事？ 歡迎到Facebook, Instagram追蹤或來信來訊跟我們提出疑問～ Email: 2propt@gmail.com 也可以在此收聽： Apple podcast: https://tinyurl.com/y97q7tms Spotify: https://tinyurl.com/ydavzqxu Google podcast: https://tinyurl.com/yd86pbcl YouTube channel: https://tinyurl.com/y82ewo5b Music by Elizabeth's Groove by Amarià @amariamusique Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: bit.ly/elizabeths-groove Music promoted by Audio Library youtu.be/-MO-mrBlo5s Reference: Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial [published correction appears in Lancet. 2023 Jun 17;401(10393):2040]. Lancet. 2023;401(10391):1866-1877. Caneiro JP, Smith A, Rabey M, Moseley GL, O'Sullivan P. Process of Change in Pain-Related Fear: Clinical Insights From a Single Case Report of Persistent Back Pain Managed With Cognitive Functional Therapy. J Orthop Sports Phys Ther. 2017;47(9):637-651.

What are the difficulties of pursuing a research career? How do hard choices and decisions affect your path? And what does an ideal mentor-mentee relationship look like? Dan Erkes, Senior Editor at The Lancet, speaks with Laura Marcela Aguirre-Martínez, a member of the youth advisory panel of The Lancet Child and Adolescent Health, and Lyda Osorio, an associate professor at the Universidad del Valle about moving through one's career.You can see all of our Spotlight content relating to research for health here:https://www.thelancet.com/lancet-200/research-for-health?dgcid=buzzsprout_tlv_podcast_lancet200_rfhFind out more about how The Lancet is marking its 200th anniversary with a series of important spotlights here:https://www.thelancet.com/lancet-200?dgcid=buzzsprout_tlv_podcast_lancet200_rfhContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Access to effective oral emergency contraception is vital, now more than ever. While use of either levonorgestrel or ulipristal is endorsed by the ACOG, pharmacodynamic and clinical data does show that ulipristal has the efficacy advantage. Although the process of ovulation is directed by the LH surge, it is also put into action by prostaglandin resulting from COX2 activity. So, can the addition of a COX2 inhibitor increase the efficacy of Plan B when taken as a combo? A new study published 24 hrs ago in the Lancet provides some exciting data. We will cover this new RCT, and more, in this episode.

Dr. Barbara Weinstein and Dr. Jan Blustein interpret the results of the ACHIEVE study recently published in The Lancet and address common misunderstandings of the data. The experts explain the difference between risk and risk factor, as well as correlation and causation.

The definition of recurrent pregnancy loss (RPL) in the US is 2 or more consecutive failed clinical pregnancies documented by ultrasound or histopathology, while, in the United Kingdom, the definition is as having 3 or more consecutive early pregnancy losses. Up to 50 percent of cases of recurrent pregnancy loss lack a clear etiology. Where do we stand, in 2023, in regards to our understanding of the effects of inherited thrombophilias on recurrent pregnancy losses? Do they cause recurrent ABs? Does LMWH help? In this episode, we will summarize a June 2023 publication in the Lancet that provides a clear answer.

這次主題很長所以分為兩集 先跟大家討論為什麼認知功能療法對物理治療師很重要 以及認知功能療法的基本原則 下集會有更多細節盡請期待囉！ Timecode: 00:30 台大操作治療學課程相關澄清：基礎物理治療學、實證操作治療學 12:40 本篇CFT case study 簡介 17:30 為什麼spinal pain 容易發展成慢性疼痛 20:15 疼痛是多面向的概念：認知、情緒、行為改變…等，運動為什麼沒辦法完全解決疼痛 25:00 物理治療師也可以學得起來認知、行為介入的技巧嗎？ 27:40 CFT與其他常見的心理治療方式的相同之處（認知行為療法, CBT；接受與承諾療法, ACT…等） 29:00 共同原則(1)以病人為中心的問診(patient-center interview) 31:30 多專業介入處理慢性疼痛與物理治療師使用CFT的差別 35:30 疼痛強度很高無法被控制的處理方法 38:30 與病人一起達成共識，一起決定要怎麼治療 41:20 病人的認知、想法、信念如何被改變？蘇格拉底式對話(Socratic conversation) 46:25 漸進式暴露、生活型態改變 歡迎到Facebook, Instagram追蹤或來信來訊跟我們提出疑問～ Email: 2propt@gmail.com 也可以在此收聽： Apple podcast: https://tinyurl.com/y97q7tms Spotify: https://tinyurl.com/ydavzqxu Google podcast: https://tinyurl.com/yd86pbcl YouTube channel: https://tinyurl.com/y82ewo5b Music by Elizabeth's Groove by Amarià @amariamusique Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: bit.ly/elizabeths-groove Music promoted by Audio Library youtu.be/-MO-mrBlo5s Reference: Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial [published correction appears in Lancet. 2023 Jun 17;401(10393):2040]. Lancet. 2023;401(10391):1866-1877. Caneiro JP, Smith A, Rabey M, Moseley GL, O'Sullivan P. Process of Change in Pain-Related Fear: Clinical Insights From a Single Case Report of Persistent Back Pain Managed With Cognitive Functional Therapy. J Orthop Sports Phys Ther. 2017;47(9):637-651.

How can clinical research better involve and recognise those with lived experience? Ensuring diverse representation and removing barriers to trial participation is essential for equitable health research, but key voices are being missed. Senior editor at The Lancet Callam Davidson is joined by trialist Otavio Berwanger and consumer adviser Vicki Grey to discuss the benefits and challenges of patient and public involvement, in the first of a series of podcasts spotlighting research for health.You can see all of our Spotlight content relating to research for health here:https://www.thelancet.com/lancet-200/research-for-health?dgcid=buzzsprout_tlv_podcast_lancet200_rfhFind out more about how The Lancet is marking its 200th anniversary with a series of important spotlights here:https://www.thelancet.com/lancet-200?dgcid=buzzsprout_tlv_podcast_lancet200_rfhContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Jones CMP, Day RO, Koes BW, et al. Lancet. Published Ahead of Print. doi:10.1016/S0140-6736(23)00404-X Due to copyright laws, unless the article is open source we cannot legally post the PDF on the website for the world to download at will. Brought to you by CSMi – https://www.humacnorm.com/ptinquest Learn more about/Buy Erik's courses – The Science PT Support us on the Patreons! Music for PT Inquest: “The Science of Selling Yourself Short” by Less Than Jake Used by Permission Other Music by Kevin MacLeod – incompetech.com: MidRoll Promo – Mining by Moonlight

Evolutionary psychologist, Doug Lisle, PhD and social scientist, Jen Howk, PhD discuss a very misleading graph in a recent paper published in Lancet Journal along with the following listener questions: 1.To what extent would you say children, money and marriage contracts keep sub-par relationships intact today vs. the lesser stickiness of relationships in the stone age. This isn't always a bad thing, right? Parents are raising kids and everyone gets to keep more of their wealth. What's the harm- why bother splitting things up in the hopes of finding a magic 10. Isn't the conservation of energy circuit just doing what it does? 2. I am stuck in a loveless marriage. I had a steady career making six figures as a pharmacist. I hated my job, but I was stuck because I was over $500,000 in debt. I then met a rich man who promised me if I married him I wouldn't have to work another day in my life. He paid off my student debt. So I agreed to marry him. Five years later, I am miserable. I never loved him, but I also feel like I have no purpose in life. I do nothing besides sleep, eat, exercise and attend social events. He has maids, cooks, nannies and tutors taking care of everything a woman normally would. The sex is awful, most of the time I just lie there waiting for him to finish and pretend to enjoy it. He loves and is attracted to me, but now even the sight of him repulses me even though he did nothing wrong. Now I am stuck in a dilemma: do I stay in a loveless marriage and comfortable life, forgoing my chance at ever finding true love, or do I leave, go back to a job I hate and have a chance at finding true love? I am a 32 year old female and he is 45 3. Dear doctors. I've been with my wife for a couple of decades. She was always very physically beautiful and I was very overrewarded up until we had kids several years ago. She is still the best person I know, however she has lost the looks and the dopamine doesn't drive me to seek her the way it use to. I've tried to talk to her about this, but she is pretty firm in her stance that I have to take it or leave it. I love my kids too much to leave the relationship, but I know deep down I would be happier with someone who I am attracted to physically. Do I do what my dad did and stick out an unhappy marriage for the kids? Or do I make the exit plan that most men seem to always do?  Copyright Beat Your Genes Podcast Host: Nathan Gershfeld                               Interviewee: Doug Lisle, Ph.D. and Jen Howk, Ph.D. Podcast website:  www.BeatYourGenes.org True to Life seminars with Dr. Lisle and Dr. Howk : www.TrueToLife.us   Intro & outro song: City of Happy Ones · Ferenc Hegedus  

Lucca Cirilo e Frederico Amorim trouxeram tudo que você precisa saber sobre vacinação pra dengue: quais os tipos, quais as indicações e contraindicações e qual as coisas novas que ainda vão surgir! Referências Referências episódio: 1. https://sbim.org.br/images/files/notas-tecnicas/nota-tecnica-sbim-sbi-sbmt-qdenga-v4.pdf 2. Patel SS, Rauscher M, Kudela M, Pang H. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clin Infect Dis. 2023 Feb 8;76(3):e1350-e1359. doi: 10.1093/cid/ciac418. PMID: 35639602; PMCID: PMC9907483. 3. Biswal S, Borja-Tabora C, Martinez Vargas L, Velásquez H, Theresa Alera M, Sierra V, Johana Rodriguez-Arenales E, Yu D, Wickramasinghe VP, Duarte Moreira E Jr, Fernando AD, Gunasekera D, Kosalaraksa P, Espinoza F, López-Medina E, Bravo L, Tuboi S, Hutagalung Y, Garbes P, Escudero I, Rauscher M, Bizjajeva S, LeFevre I, Borkowski A, Saez-Llorens X, Wallace D; TIDES study group. Efficacy of a tetravalent dengue vaccine in healthy children aged 4-16 years: a randomised, placebo-controlled, phase 3 trial. Lancet. 2020 May 2;395(10234):1423-1433. doi: 10.1016/S0140-6736(20)30414-1. Epub 2020 Mar 17. Erratum in: Lancet. 2020 Apr 4;395(10230):1114. PMID: 32197105. 4. Patel SS, Rauscher M, Kudela M, Pang H. Clinical Safety Experience of TAK-003 for Dengue Fever: A New Tetravalent Live Attenuated Vaccine Candidate. Clin Infect Dis. 2023 Feb 8;76(3):e1350-e1359. doi: 10.1093/cid/ciac418. PMID: 35639602; PMCID: PMC9907483.

重啟慢性疼痛的篇章 這次先跟大家討論什麼是認知功能療法(CFT) 之後會講到如何應用的部份 請大家盡請期待囉！ Timecode: 00:28 長輩群組椎間盤突出治療討論 14:00疼痛科學、神經科學的相關知識為什麼對物理治療師很重要？下背痛的醫療支出已經超越癌症及糖尿病的醫療支出！推薦JOSPT pain science in practice 系列文章！ 23:10 簡介發表在The Lancet的CFT隨機對照試驗，CFT不只有效還比較省錢 26:30 沒有相關背景知識的物理治療師可以學得會嗎？ 30:15 CFT三面向：理解疼痛(making sense of pain)、控制下暴露(exposure with control)、生活模式改變(lifestyle change) 33:00 加入動作感應器生理回饋在CFT的效果？ 37:00 Multimodal treatment 多樣介入模式花費太高 40:00 2pro PT 為何想再講一次慢性疼痛 歡迎到Facebook, Instagram追蹤或來信來訊跟我們提出疑問～ Email: 2propt@gmail.com Reference: Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial [published correction appears in Lancet. 2023 Jun 17;401(10393):2040]. Lancet. 2023;401(10391):1866-1877.

Respected medical researchers' bombshell study, indicating that COVID shots directly caused or contributed to up to 74% of reviewed deaths, was quickly censored within 24 hours of publication in The Lancet. https://tinyurl.com/bdh8y3tt #BobUnruh #WNDNewsCenter #newstudy #COVID19 #COVIDshots #COVIDvaccines #vaccinations #vaccinedeaths #coronaviruspandemic #Bidenadministration #vaccinemandate #TheLancet #VancouverWa #ClarkCountyWa #ClarkCountyNews #ClarkCountyToday

Welcome to a special summer bonus episode of The Food Professor podcast recorded live in our on-site podcasting studio at the SIAL Food Innovation show in Toronto.  Over three great days in May, Sylvain and I met dozens of food innovators and thought leaders; these are their stories.  We're sure you will enjoy hearing these incredible interviews as much as we enjoy hosting the conversations. Stay tuned for season four of The Food Professor podcast, Canada's top food industry and Canadian-produced independent management podcasts, when we return live on the mic Thursday, September 21stOn this episode meet Gurth Pretty, Cheese Professional, owner, Lakeview Cheese Galore in Mississauga.If you like what you heard, please follow us on Apple, Spotify, or your favourite podcast platform so that you can catch up with all our great interviews, including celebrity chef, restauranteur and entrepreneur Chuck Hughes from Montreal.Have a safe summer, everyone.About GurthGurth M. Pretty is a passionate Canadian cheese professional.He is a member of the Toronto Cheese Education Guild Class of 2006, the first class of cheese professionals.Gurth's knowledge of cheese was developed during his research for his first book, The Definitive Guide to Canadian Artisanal and Fine Cheese (Whitecap Books 2006), soon followed by The Definitive Canadian Wine and Cheese Cookbook (Whitecap Books 2007), co-authored with writer and wine judge Tony Aspler.Canadian cheese received more international attention when he was asked to contribute to The World Book of Cheese (DK Books 2009). The book includes his entries on 24 Canadian cheeses.He has participated as a judge in the following competitions* Canadian Cheese Grand Prix 2009, 2011 and 2013* American Cheese Society competitions in 2011, 2018 and 2019.* Judge at the 2016 and 2018 Canadian Cheese Awards and* the 2016 and 2020 World Championship Cheese Contest in Madison, Wisconsin.His involvement in the Canadian cheese industry has included the following positions* Treasurer of the Toronto Cheese Guild* Board member of the Ontario Cheese Society, and* President of the Canadian Cheese Society.In 2018, Gurth was recognized for his efforts by being invited to become a member of La Guilde Internationale des Fromagers, an international association of professional cheesemakers, ripeners, dairy processors and cheese makers. It has over 6,000 members in 33 countries.From 2011 to 2019, Gurth was the corporate cheese expert and senior specialist – deli cheese, for the Marketplace division of Loblaw Companies Limited, Canada's largest food retailer. About UsDr. Sylvain Charlebois is a Professor in food distribution and policy in the Faculties of Management and Agriculture at Dalhousie University in Halifax. He is also the Senior Director of the Agri-food Analytics Lab, also located at Dalhousie University. Before joining Dalhousie, he was affiliated with the University of Guelph's Arrell Food Institute, which he co-founded. Known as “The Food Professor”, his current research interest lies in the broad area of food distribution, security and safety. Google Scholar ranks him as one of the world's most cited scholars in food supply chain management, food value chains and traceability.He has authored five books on global food systems, his most recent one published in 2017 by Wiley-Blackwell entitled “Food Safety, Risk Intelligence and Benchmarking”. He has also published over 500 peer-reviewed journal articles in several academic publications. Furthermore, his research has been featured in several newspapers and media groups, including The Lancet, The Economist, the New York Times, the Boston Globe, the Wall Street Journal, Washington Post, BBC, NBC, ABC, Fox News, Foreign Affairs, the Globe & Mail, the National Post and the Toronto Star.Dr. Charlebois sits on a few company boards, and supports many organizations as a special advisor, including some publicly traded companies. Charlebois is also a member of the Scientific Council of the Business Scientific Institute, based in Luxemburg. Dr. Charlebois is a member of the Global Food Traceability Centre's Advisory Board based in Washington DC, and a member of the National Scientific Committee of the Canadian Food Inspection Agency (CFIA) in Ottawa. About MichaelMichael is the Founder & President of M.E. LeBlanc & Company Inc. and a Senior Advisor to Retail Council of Canada and the Bank of Canada as part of his advisory and consulting practice. He brings 25+ years of brand/retail/marketing & eCommerce leadership experience with Levi's, Black & Decker, Hudson's Bay, Today's Shopping Choice and Pandora Jewellery.   Michael has been on the front lines of retail industry change for his entire career. He has delivered keynotes, hosted fire-side discussions with C-level executives and participated worldwide in thought leadership panels. ReThink Retail has added Michael to their prestigious Top Global Retail Influencers list for 2023 for the third year in a row. Michael is also the president of Maven Media, producing a network of leading trade podcasts, including Remarkable Retail , with best-selling author Steve Dennis, now ranked one of the top retail podcasts in the world. Based in San Francisco, Global eCommerce Leaders podcast explores global cross-border issues and opportunities for eCommerce brands and retailers. Last but not least, Michael is the producer and host of the "Last Request Barbeque" channel on YouTube, where he cooks meals to die for - and collaborates with top brands as a food and product influencer across North America 

Content warning: Discussion of traumatic experiencesSophia Davis, Senior Editor at The Lancet Psychiatry, is joined by Judith Lewis Herman, Duane Booysen, and Angela Sweeney to talk about the impact of trauma and routes to recovery. They discuss how ideas about trauma have changed over time, and about how trauma happens not just to an individual but within social contexts, and the recovery or healing from trauma does too. They also consider the importance of the context of different countries, of survivor-led research, and of social justice for trauma. You can see all of our Spotlight content relating to mental health here:https://www.thelancet.com/lancet-200/mental-health?dgcid=buzzsprout_tlv_podcast_lancet200_uhcFind out more about how The Lancet is marking its 200th anniversary with a series of important spotlights here:https://www.thelancet.com/lancet-200?dgcid=buzzsprout_tlv_podcast_lancet200_uhcContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

“Aspartam kommer på WHO's kræftliste.” Det var én af de mange overskrifter, man kunne læse, da det for to uger siden blev afsløret, at Verdenssundhedsorganisationen ville klassificere sødemidlet som ‘muligvis kræftfremkaldende'. Nu er WHO udkommet med deres begrundelse – men siger samtidig, at det ikke er skadeligt at indtage. Og det har – forståeligt nok – skabt både frygt og forvirring. I denne episode gennemgår vi WHO pressemeddelselse samt de forskellige instanser, IARC og JECFA, der er involveret i asapartam-udmeldingen og hvad der egentlig er op og ned på kategoriseringen af aspartam. Vi besvarer ud fra det spørgsmålet: Er der grund til bekymring for aspartam skulle være skadeligt at indtage? Hvis du vil støtte podcasten, så finder du vores sponsor Zetland lige her. Du får to måneders lytbar, reklamefri, dommedagsfri kvalitetsjournalistik for 50 kroner i alt. Det er under en tredjedel af normalprisen: zetland.dk/slutmedforbudt Ting, vi nævner i podcasten: Elsøes Instagram-opslag, der opsummerer hele sagen: https://www.instagram.com/p/CutgghKNoKh/  Pressemeddelelsen fra WHO, der både indeholder konklusionen fra IARC og JECFA: https://www.who.int/news/item/14-07-2023-aspartame-hazard-and-risk-assessment-results-released Artiklen i Lancet, der indeholder IARC's begrundelse for vurderingen af aspartam: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00341-8/fulltext JECFA's begrundelse for stadig at vurdere, at aspartam er sikkert at indtage: https://www.who.int/publications/m/item/ninety-sixth-meeting-joint-fao-who-expert-committee-on-food-additives-(jecfa) IARC's database over alt, de har har vurderet til dato: https://monographs.iarc.who.int/list-of-classifications/  EFSA's kritik af de italienske aspartam-forsøg, der – som de eneste – konkluderede, at aspartam var kræftfremkaldende i mus: https://www.efsa.europa.eu/en/news/efsa-assesses-new-aspartame-study-and-reconfirms-its-safety 

Dr. Supriya Mohile , Dr. William Dale, and Dr. Heidi Klepin discuss the updated guideline on the practical assessment and management of age-associated vulnerabilities in older patients undergoing systemic cancer therapy. They highlight recent evidence that prompted the guideline update, and share the updated evidence-based recommendations from the panel, focusing on geriatric assessment-guided management. Dr. Mohile also reviews what the expert panel recommends should be included within a geriatric assessment, and Dr. Dale highlights the Practical Geriatric Assessment tool, aimed at helping clinicians implement a geriatric assessment. Dr. Klepin comments on the impact for both older adults with cancer and their clinicians, and reviews outstanding questions and challenges in the field. Read the full guideline, "Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the update and review authors' disclosures of potential conflicts of interest disclosures in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.00933. See also the Practical Geriatric Assessment tool and associated videos (How to do a Geriatric Assessment, What to do with the Results of a Geriatric Assessment) mentioned in the podcast episode. Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one at asco.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Dr. William Dale from City of Hope National Medical Center, Dr. Heidi Klepin from Wake Forest Baptist Comprehensive Cancer Center, and Dr. Supriya Mohile from University of Rochester Medical Center—co-chairs on “Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update.”  Thank you for being here, Dr. Dale, Dr. Klepin, and Dr. Mohile. Dr. William Dale: Nice to see you. Thanks for having us. Brittany Harvey: Then, before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensures that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including our guests joining us on this podcast episode today, are available online with the publication of the guideline in the Journal of Clinical Oncology linked in the show notes.  Diving into the content of this guideline first, Dr. Dale and Dr. Mohile, can you speak to what prompted an update of this ASCO guideline on the practical assessment and management of age-associated vulnerabilities in older patients undergoing systemic cancer therapy, which was previously published in 2018? Dr. William Dale: Sure. Yes. In 2018, that was the very first guideline for older adults that ASCO had created, and that was based on work that had been done up to that time, focused on chemotherapy toxicities. And to summarize what was put out at that time, the evidence was thought to be strong enough for doing geriatric assessments. And these are specialized assessments across a number of domains, including functional impairments, cognitive losses, social impairments, etc. But to do these kinds of geriatric assessments with validated tools; that a certain selection of these domains to cover everything that was relevant; to conduct non-cancer prognostication so that for decision-making purposes, if someone were to have their cancer cured, what would be their prognosis, and help make decisions about giving chemotherapy and what doses; and then to enact geriatric assessment-guided target interventions was the fourth recommendation. And so that's where we were in 2018.  In 2020 at ASCO, there was an oral session that had four randomized controlled trials that enrolled older adults. And in that was kind of the signal that there was more coming. And in 2021, two big trials that are practice-changing were published. One led by Dr. Mohile in Lancet that we call the GAP70+ study, and another one was published in JAMA Oncology. And they essentially showed the same thing, which was that GA-guided interventions could change the primary outcome, which was to reduce chemotherapy toxicity up to 20%, and also to affect a number of other outcomes. That, along with a number of other trials that have since come out and are included in the upcoming guidelines, and made it a high priority to update these guidelines. So that's where we got from there to here. And I think it's worth saying a few words about these new trials, particularly the GAP and GAIN studies. So the GAIN study included patients who were 65 and older who were starting systemic chemotherapy and looked at the likelihood of having chemotherapy toxicity as described and looked at a number of other outcomes. Most importantly, it showed that chemotherapy toxicity could be reduced with these interventions based on the geriatric assessment from about 60% to about 50%. It also showed that the likelihood of completing advanced directives would go up by around 25%. And importantly, there was no impact after all of the use of the geriatric assessments on mortality. So patients were living just as long, but they were having less toxicity and they were having more goal-concordant care. And at almost the same time, the GAP study came out, which I would hand over to Dr. Mohile to describe. Dr. Supriya Mohile: Thank you, Dr. Dale. I agree that it was time for an update, and I'm glad ASCO partnered with us to do this. I'll also just mention that Dr. Dale, Dr. Klepin, and I lead the Cancer and Aging Research Group, and many of the original predictive models that showed that geriatric assessment could help us identify patients at highest risk for toxicity were designed by Cancer and Aging Research Group investigators. And that's what informed the first guideline. I'll mention Dr. Arti Hurria, who unfortunately passed away a few years ago, and she led some of the first large studies that developed these predictive models. We built on that data in both GAP and GAIN studies to show that the geriatric assessment—when you assess and provide management—can reduce chemotherapy toxicity.   Like GAIN, GAP70+ implemented a geriatric assessment intervention that both assessed and provided management to older adults. There were some key differences. In GAP70+, the patients had advanced cancer, whereas, in the GAIN study, it was a more generalizable population of patients with both curative intent and advanced cancer. And in the GAP70+ study, we enrolled patients who already had geriatric assessment domain impairments, meaning that these patients were more vulnerable because of those aging-related conditions. We were trying to enroll patients who are traditionally excluded from therapeutic clinical trials. The GAP70+ study was done in oncology offices by Community Oncology practices.  So this was what I think was really interesting, in that geriatricians were not involved in implementing the geriatric assessment in this study. Oncologists received the assessment information from their team, and they're the ones that implemented the recommendations. We found in GAP70+ that not only chemotherapy toxicity was reduced, that we were able to reduce the prevalence of falls and reduce the incidence of polypharmacy, which are important geriatric outcomes for older adults. We included patients who were receiving chemotherapy, but also patients who are receiving high-risk targeted agents in GAP70+, which also leads us to believe that these interventions are important for patients who are receiving treatments other than chemotherapy.  So we believe these two trials, plus others, really inspired the ASCO guidelines. Brittany Harvey: Absolutely. I appreciate you both for providing that context and background and some of the new evidence that's informed this latest update. So then I'd like to move into some of the updated recommendations of the guideline. So, Dr. Mohile, what is the updated recommendation from the panel regarding the role of geriatric assessment in older adults with cancer? Dr. Supriya Mohile: So the first guideline really focused on the assessment piece, what should be assessed, and why, which we still incorporate in this new guideline. This guideline extends now because of the randomized controlled trials into management. And when we think about geriatric assessment, we think about two pillars of management. One is how geriatric assessment influences cancer decisions, that includes what treatments to provide, what dose to provide. And then the second is how geriatric assessment can influence management recommendations that are supportive care based that address some of the geriatric assessment domain impairments.  I'll just give you an example of both. So when we see patients with advanced cancer who have geriatric assessment domain impairments who are presenting for treatment, often the doses of chemotherapy may be overtreatment because those doses were developed in therapeutic clinical trials in younger, more fit patients. And in our geriatrics world, we often think about going slow and starting low, and we may do a first cycle that's dose reduced a touch, to kind of see how the patient does physiologically with that first cycle. There are therapeutic clinical trials like FOCUS2 in patients with metastatic colon cancer that show the benefits of being careful with dosing in the first cycle.  So, in GAP70+, the oncologists who received information from the assessment were more likely to reduce the dose of the treatment in the first cycle which led to less toxicity but did not lead to a difference in survival, so do not compromise survival. And I think this is because we don't know the right doses for patients who have significant aging-related impairments. So that's one example of decision-making.  As examples for geriatric management recommendations that are supportive care, this can be done in almost like an algorithmic approach. So, if a patient has an impairment on a physical function test, then through the geriatrics literature we know of management recommendations that can improve outcomes like physical therapy, home safety evaluations, balance, training, fall prevention information. And if we implement those supportive care recommendations through that patient who's at risk for falls, we may prevent falls and we were able to show that in addition in GAP70+ as well as other trials showed benefits in some of those outcomes.  And so those are the two pieces that I think are newer with this guideline than with the previous guideline. We know more about how those management recommendations can improve outcomes.    Brittany Harvey: Understood. Yes. It's helpful to understand those examples of how integrating this geriatric assessment can help improve the management of care for these patients. So then you've mentioned some of the geriatric assessment domain impairments. So, Dr. Mohile, what does the guideline recommend should be included within a geriatric assessment? Dr. Supriya Mohile: This was a really great question for us to rise and think about, as part of this guideline and as a panel, we went back and forth with all of the authors to try to think about what is the most streamlined number of domains that should be assessed? What are the highest priority domains that, if you could only do a few things in a busy oncology clinic, which are the ones that oncologists should have to do because without doing them, they won't have relevant information to inform treatment decisions or to improve the outcomes of their patients?  And so when we think about geriatric assessment, there has been literature to show that almost all of the domains we do are important in identifying patients who are at risk of poor outcomes. These include physical function, cognitive function, emotional health, comorbidities, polypharmacy, nutritional status, and social support. That sounds like a lot, but we do many of those assessments sort of naturally in oncology clinics. There are just a few that are not done as standard. For example, it is not standard for oncologists to assess cognition using a validated screening test for cognition. And we know that recognizing patients who may have cognitive impairment is really important in identifying vulnerabilities and providing support systems in place so patients who are receiving treatment can go through treatment safely.   Other things, like just doing a formalized nutritional assessment, really bringing in the caregiver, are done not in a standard way. And so what the geriatric assessment allows is for us to assess each of those domains in a standard way. When we're communicating to our colleagues and tumor boards, we can describe vulnerabilities in a standard way. And we're moving now past the eyeball test, which is different for different clinicians, and having more objective ways of describing health status to be able to have a common language across studies and in clinical care. Brittany Harvey: That's helpful to understand moving past the less formal approach to geriatric assessment and making it more standardized.  So then, Dr. Dale, this guideline offers a specific tool, the Practical Geriatric Assessment, as an option for clinicians conducting a geriatric assessment. What is this tool and where can clinicians access it? Dr. William Dale: Very good question. Just to set the context a bit, after hearing about all the evidence that we've just described. We did do some work as a task force through ASCO and through some work that Dr. Klepin and her colleague have done to understand now that the guidelines in 2018 had come out, they weren't really being used. So when we asked, about 25% of people would say they were using them very much, even though we saw in these large studies that we did, that those who were using the guidelines were changing their practice significantly in the ways that Dr. Mohile mentioned. And this was among a large group of community oncologists.  So we have been breaking down the geriatric assessment into the most concise, most straightforward, and easiest-to-use version of the geriatric assessment, maintaining its validity and maintaining the number of domains. We really tried to make it simple. So the Practical Geriatric Assessment is not the only tool, but it is a tool that accomplishes this practical charge to make it accessible to community oncologists while also being valid. So those domains that Dr. Mohile mentioned physical function, functional status, nutrition, social support, psychological considerations, comorbidities are all in the Practical Geriatric Assessment.   But what we've done is boil it down to here's a very specific tool that we think is valid but easily applied. Here are the very specific thresholds that tell you when a deficit has been identified and then gives recommended actions to be taken, whether it's in decision-making or in other interventions like a referral to somebody, perhaps physical therapy, or a cognitive specialist, all of which come from the GAP. So this tool is designed to be very straightforward and practical, but still cover all the relevant domains. And it will be made available through both the ASCO website and through the Cancer and Aging Research Group website so that people can access it easily. Brittany Harvey: That sounds like a real challenge that the ASCO working group took on to create a comprehensive yet practical tool for clinicians to use. We'll also provide some links for people to access this in the show notes of this podcast episode.   So then I want to move on. Dr. Klepin, in your view, how will this guideline update impact both clinicians and older adults with cancer?  Dr. Heidi Klepin: Yes. Thank you. As was mentioned, for clinicians, the guidelines provide an overview of new evidence and concrete recommendations to address the challenge experienced every day in practice, that of providing personalized care in the context of age-related conditions to maximize benefits and minimize the risk for older adults with cancer. The evidence summary will educate clinicians on key outcomes that can be positively impacted by use of geriatric assessment, including decreasing treatment toxicity, enhancing decision-making, and improving communication and patient-caregiver satisfaction.  And this information on outcomes is really critical to informing the use of geriatric assessment in practice. We hope that the evidence-based recommendations with the provision of the practical geriatric assessment and the associated trigger table to guide management strategies will empower clinicians to incorporate geriatric assessment into their workflow by helping them overcome some of those known barriers that Dr. Dale mentioned, such as lack of time and uncertainty about which measures to use and what to do with the information once you have it. So, we anticipate that providing clear recommendations and accompanying readily available materials to support the implementation that clinicians in both community and academic practices will be able to use the geriatric assessment and incorporate it into routine care. For patients, we anticipate that the guideline recommendations would translate into increased use and access to this type of assessment as part of their routine oncology care. So, we hope that our patients will actually be able to access this regardless of whether they're receiving care at a specialized academic center versus a community oncology clinic. So, by doing this, we would extend the proven benefits of geriatric assessment, including lower rates of side effects, experiencing fewer hospitalizations, and improving satisfaction to older adults regardless of where they receive treatment.   And we feel like this is critically important, since currently, most older adults receive cancer care in community oncology clinics without access, as was mentioned, to any geriatric specialty care. So, as more older adults have the opportunity to participate in this type of assessment as part of routine care in their oncology clinics, they'll be able to discuss the results of the assessment with their healthcare providers, which can help them make better-informed decisions and engage, I think, more completely in what we would consider patient-centered decision making. And ultimately, we would hope that the guidelines would provide an evidence-based and practical strategy for improving the quality of care received by older adults with cancer.   Dr. Dale, would you be interested in commenting a little bit more on the patient perspective informed by our patient partners on the guideline panel? Dr. William Dale: Yeah. Thank you, Dr. Klepin. Very well said. Yeah, our guideline panel, just to fill out the picture of that, included our patient partners, along with a wide diversity of perspectives. We had experts in geriatric oncology, but we had community oncologists who take care of cancer patients. We have people from across the country. We had different backgrounds and different levels of experience. But to focus on the patients for a group that we've worked with for some time called SCOREboard, and they were some of the strongest voices on this.  Whenever people said, “Well, do we really need to require this?” The patient partners were insistent that this be included as a requirement as much as possible for what happens. I think one of the most important roles they've played is as advocates for this. If I can, when the community oncologists are having some concerns about how hard this would be or how difficult it might be, the patient partners have been the first to say, we need to find a way to do it and insist that we empower the patients to ask for it. So, one of the hopes for all of these guidelines is also that it get disseminated to patients who can self-advocate as they go forward and have tools that will be made available for them to use in this self-advocacy. Brittany Harvey: Definitely, that self-advocacy is important and the geriatric assessment is critical for optimal care for older adults.  So, then we've talked a lot about the new evidence regarding geriatric assessment and also making it easier for clinicians to implement the geriatric assessment, but Dr. Klepin, what are the outstanding questions and challenges regarding geriatric assessment in older adults with cancer?  Dr. Heidi Klepin: Thanks. So, while there's strong evidence and clear rationale to incorporate geriatric assessment into routine clinical care, there are outstanding questions and challenges that we have to consider. First and foremost, still remains a challenge of implementation. As mentioned, we hope that the Practical Geriatric Assessment, the detailed recommendations, and the associated educational materials on what to do with the geriatric assessment information will help overcome implementation barriers for many. But we recognize that more work needs to be done to both train providers to facilitate behavior change as well as to tackle clinic and healthcare system barriers to routine use.  And along these lines, we also recognize that it's important to educate patients and caregivers about the role of geriatric assessment and its value in order to optimize uptake in community clinics. We want all of our patients to be as enthused and recognize the importance of the geriatric assessment, as our colleagues on the recommendation panel did. Another consideration is the challenge of tailoring use of geriatric assessment to specific disease and treatment settings. And more research is underway testing geriatric assessment and management strategies in varied disease settings, as well as with varied treatment types and intensities.  And finally, I would suggest that another challenge is the lack of routine incorporation of geriatric assessment measures into cancer clinical trials. And this will really be necessary to interpret clinical trial data for older adults optimally and to reinforce the value of routine geriatric assessment in clinical care. Brittany Harvey: Absolutely. These are key points for moving forward and looking forward to additional research in this area and maybe future guideline updates down the line.  So, I want to thank you all so much for your work on updating this guideline and for your time today. Dr. Dale, Dr. Klepin, and Dr. Mohile.  Dr. Heidi Klepin: Thank you for having us.  Dr. William Dale: Yeah, thanks for having us here. We're delighted to be talking about this.  Dr. Supriya Mohile: Thank you.  And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store.  If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.  The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-337 Overview: There has been uncertainty as to the best time for patients to take blood pressure medications. Tune in as we review the Treatment in Morning versus Evening (TIME) study, which assessed whether morning or evening dosing improves cardiovascular outcomes. Episode resource links: Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-1425.  Guest: Alan M. Ehrlich MD, FAAFP   Music Credit: Richard Onorato

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-337 Overview: There has been uncertainty as to the best time for patients to take blood pressure medications. Tune in as we review the Treatment in Morning versus Evening (TIME) study, which assessed whether morning or evening dosing improves cardiovascular outcomes. Episode resource links: Mackenzie IS, Rogers A, Poulter NR, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-1425.  Guest: Alan M. Ehrlich MD, FAAFP   Music Credit: Richard Onorato

The Secret Service ended the White House cocaine investigation with no findings. Gal Luft, the informant in the Biden corruption case, was indicted for lobbying for a Chinese energy company. The FBI is a joke. Chairman Jim Jordan sent a funding recommendation to protect Americans' fundamental civil liberties. John Kerry believes the big problem with the war on Ukraine is the blowing up of septic tanks and the release of methane into the atmosphere. Speaking of Ukraine, Biden told a CNN reporter that the reason we are sending cluster bombs to Ukraine is that we are short on ammunition. A Lancet study on Covid vaccine autopsies found that 74% of the deaths were caused by the vaccine. Former New York Mayer, Bill de Blasio, and his out-lesbian wife are separating.

Dr Peter McCullough returns to The Jeff Dornik Show with an update on what we've learned recently about the covid jabs. The ramifications of these bioweapon injections are only just beginning to be realized, and we've barely scratched the surface of just how harmful these truly are.There was a recent paper that Dr McCullough submitted to Lancet stating that 73.9% of deaths among those vaccinated against covid-19 were caused by the jab itself. Unfortunately, after record amount of traffic to the paper, Lancet pulled it completely off of their site, given that they want everyone to continue getting their boosters. We also discussed the 2024 Presidential Election and Dr McCullough's thoughts on the candidates. He feels as if no one is handling the covid issue properly. President Donald Trump owes the American people an apology for his handling of covid and the jabs, with hundreds of thousands of people dying because of his decisions. And then RFK Jr is treating the issue of vaccines like a lawyer litigating his case instead of as an executive leading the country. It was definitely a fascinating conversation that needs to be heard in its entirety. Dr McCullough also provides his protocol for protecting yourself from serious injury if you've been jabbed or have had covid multiple times. Dr Peter McCullough is the Chief Scientific Officer of The Wellness Company, and is one of the most published cardiologist ever in America, with over 1,000 publications and 660 citations in the National Library of Medicine and is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Subscribe to Dr McCullough's Substack: https://petermcculloughmd.substack.com Subscribe to this show on Rumble and Apple Podcasts. Subscribe to Jeff Dornik's Substack at https://jeffdornik.substack.com. Sign up for pickax, the social media platform that protects free speech, is not beholden to Big Tech, has algorithms that amplify your voice and provides monetization opportunities for content creators. https://pickax.com Join the millions of patriots who fall asleep every night on one of Mike Lindell's MyPillows. Support a pro-America and conservative company by using discount code FFN for insane deals at https://mypillow.com Start your day with a cup of freedom… Freedom First Coffee that is! It's 100% organic, fire-roasted and tastes like FREEDOM. Use discount code JEFF. https://freedomfirstcoffee.com Protect your wealth from the Biden-induced inflation. Buy gold from Our Gold Guy. Let him know that Jeff Dornik sent you. https://ourgoldguy.com Detox your body from heavy metals and toxins from the zeolite detox recommended by Dr Sherri Tenpenny! Click here for $50 off: https://jeffdornik.thegoodinside.com/pbx-trial-offer-10c2020/ Pre-order Jeff Dornik's book Following the Leader, which explains how the intelligence agencies use cult tactics to brainwash the masses and push propaganda through cult mentality. https://jeffdornik.com/ftl

The hottest day on record is always determined by transient markers, adjustments of context, confirmation bias, and computer modeling. The “hottest day” can be determined by a specific location, at a certain time, on an isolated day, during a specific month, when numbers are averaged out and put into a computer model. Recent data from Main's Climate Reanalyzer computer model, for example, have been used to state as fact that this is the hottest year on record anywhere on Earth. However, the National Oceanic and Atmospheric Administration, according to the APP, “issued a note of caution about the Maine tool's findings, saying it could not confirm data that results in part from computer modeling, saying it wasn't a good substitute for observations.” In 2021, Yale published a similar report, stating ‘Death Valley, California, breaks the all-time world heat record for the second year in a row'. But two problems were found with this report; one, the temperature reported by Yale was 130 and was not even “verified,” and two, the hottest day ever was recored by the National Park Service in 1913 at 134 degree F. Some of the hottest cities in the U.S. like Tucson, Arizona, are also routinely used to terrify people about the heat. Tucson's records date back to 1899 when in the fall of that year the temperature reached 107 degrees F, nearly the same temperature as was recorded in the summer of 1900 at 108. The high temperatures from 1899-2023 were all over 100, which makes sense because it is the desert in the summer. In 1990 the temperature hit 117 in June, something that has yet to officially happen again in over thirty years. The record in 2022 was 111. People are finally starting to notice that weather-maps for temperature X are being updated from green to red for the same X temperature. In fact, the color scale for temperature itself is eerily reminiscent of the terrorist alert system, which, like this year's supposed record high on July 4th weekend, always peaked with terrorist alerts on July 4th. This is all despite the fact that, according to a 2015 Lancet study, the largest ever conducted on the subject of temperature, 17 people die from cold compared to every 1 death from heat. The fact that Solar Cycle 25 is not only reaching its peak, but is more active and powerful than expected - with the sun showing the most sunspots in over two decades - is a detail happily overlooked to push the same kinds of distorted narratives and statistical manipulations that drove fear of disease in recent years.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5328407/advertisement

In this episode, Charlie is joined by cardiologist Dr. Peter McCullough to discuss the Lancet study on vaccine-related fatalities, which was abruptly removed, the connection between vaccines and autism, and the escalating issue of medical censorship.

Why did the Lancet scuttle a new report analyzing deaths after Covid vaccination? And why is so little attention given to the extremely healthy outcomes of Amish children, who have far lower rates of cancer, autism, and other medical problems? Dr. Peter McCullough says it's a matter of protecting "mass vaccination at all costs." He joins Charlie to discuss how recent events, and the Covid shot backlash, are helping to turn the tide of public sentiment. Plus, former acting Attorney General Matthew Whitaker lays out how unusual Hunter Biden's sweetheart deal from DOJ was, and then explores the follow-up question: Did Merrick Garland lie to Congress, and if so, how can he be held accountable?Support the show: http://www.charliekirk.com/supportSee omnystudio.com/listener for privacy information.

Dr. Paul Alexander Liberty Hour – Why did LANCET censor our study after publishing? Is the Lancet Journal now dead on arrival (DOA)? It was a review of 325 autopsies after Covid vaccine. The study found that 74% were due to the COVID vaccine. LANCET pulled it in 24 hours. Did the vaccine makers threaten LANCET? Why would LANCET pull this study?

RFK Jr., Dr Peter McCullough, Naomi Wolf. 85% Died from Lack of Early Treatment, 74% of the deaths following mRNA vaccine injection were likely caused by the injection.   RFK Jr.- "85% of the people [in the US] who died should not have died — because they were denied early treatment, America Had the Most COVID Deaths in the World: "It's Hard to Understand Why Anthony Fauci Is a Hero" - RFK Jr. "85% of the people [in the US] who died should not have died — because they were denied early treatment," #RFKjr #FauciLied Source- Tweet from @GretchenOO8   Doctors Censored by The Lancet in Paper that Found 74% mRNA Vaccine-Related Cause of Death Dr Peter McCullough, Dr. Harvey Risch, and colleagues were censored by the formerly respected scientific journal The Lancet: their paper, removed within 24 hours, found that 74% of the deaths following mRNA vaccine injection were likely caused by the injection. Watch this video at- https://rumble.com/v2ykrv8-doctors-censored-by-lancet-in-paper-that-found-74-mrna-vaccine-related-caus.html And at- https://dailyclout.io/doctors-censored-by-lancet-in-paper-that-found-74-mrna-vaccine-related-cause-of-death/   HELP ACU SPREAD THE WORD!  Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks. Forward this show to friends. Ways to subscribe to the American Conservative University Podcast Click here to subscribe via Apple Podcasts Click here to subscribe via RSS You can also subscribe via Stitcher FM Player Podcast Addict Tune-in Podcasts Pandora Look us up on Amazon Prime …And Many Other Podcast Aggregators and sites ACU on Twitter- https://twitter.com/AmerConU . Warning- Explicit and Violent video content.   Please help ACU by submitting your Show ideas. Email us at americanconservativeuniversity@americanconservativeuniversity.com Please go to Apple Podcasts and give ACU a 5 star rating. Apple canceled us and now we are clawing our way back to the top. Don't let the Leftist win. Do it now! Thanks.   Endorsed Charities -------------------------------------------------------- Pre-Born! Saving babies and Souls. https://preborn.org/ OUR MISSION To glorify Jesus Christ by leading and equipping pregnancy clinics to save more babies and souls. WHAT WE DO Pre-Born! partners with life-affirming pregnancy clinics all across the nation. We are designed to strategically impact the abortion industry through the following initiatives:… -------------------------------------------------------- Help CSI Stamp Out Slavery In Sudan Join us in our effort to free over 350 slaves. Listeners to the Eric Metaxas Show will remember our annual effort to free Christians who have been enslaved for simply acknowledging Jesus Christ as their Savior. As we celebrate the birth of Christ this Christmas, join us in giving new life to brothers and sisters in Sudan who have enslaved as a result of their faith. https://csi-usa.org/metaxas   https://csi-usa.org/slavery/   Typical Aid for the Enslaved A ration of sorghum, a local nutrient-rich staple food A dairy goat A “Sack of Hope,” a survival kit containing essential items such as tarp for shelter, a cooking pan, a water canister, a mosquito net, a blanket, a handheld sickle, and fishing hooks. Release celebrations include prayer and gathering for a meal, and medical care for those in need. The CSI team provides comfort, encouragement, and a shoulder to lean on while they tell their stories and begin their new lives. Thank you for your compassion  Giving the Gift of Freedom and Hope to the Enslaved South Sudanese -------------------------------------------------------- Food For the Poor https://foodforthepoor.org/ Help us serve the poorest of the poor Food For The Poor began in 1982 in Jamaica. Today, our interdenominational Christian ministry serves the poor in primarily 17 countries throughout the Caribbean and Latin America. Thanks to our faithful donors, we are able to provide food, housing, healthcare, education, fresh water, emergency relief, micro-enterprise solutions and much more. We are proud to have fed millions of people and provided more than 15.7 billion dollars in aid. Our faith inspires us to be an organization built on compassion, and motivated by love. Our mission is to bring relief to the poorest of the poor in the countries where we serve. We strive to reflect God's unconditional love. It's a sacrificial love that embraces all people regardless of race or religion. We believe that we can show His love by serving the “least of these” on this earth as Christ challenged us to do in Matthew 25. We pray that by God's grace, and with your support, we can continue to bring relief to the suffering and hope to the hopeless. -------------------------------------------------------- Disclaimer from ACU. We try to bring to our students and alumni the World's best Conservative thinkers. All views expressed belong solely to the author and not necessarily to ACU. In all issues and relations, we hope to follow the admonitions of Jesus Christ. While striving to expose, warn and contend with evil, we extend the love of God to all of his children.

¿Cómo te ha afectado el calor? Jessica Ordóñez-Lancet, directora general adjunta de Climate Power en Acción, nos habla que la temperatura de la Tierra experimenta un máximo histórico por tercer día consecutivo. Edwin Pitti, nuestro corresponsal de Univision en La Casa Blanca, nos da todo la actualidad que rodea al presidente y la capital del país. Paula Lamas, Periodista en Seattle, nos da recomendaciones para viajar a la ciudad esmeralda En Contacto Deportivo, Aldo Sánchez nos acompaña para hablar de lo acontecido en la NHL, MLB y NBA, además de la actualidad del fútbol mexicano con Expansión, Liga MX Femenil y varonil. Mañana más, en Buenos Días América, no olvides en conectarte. Si te gusto, recuerda compartir con tus amigos que pueden encontrarnos en la App de UFORIA o en cualquier plataforma de podcast. Envíanos tus comentarios, inquietudes o sugerencias, a nuestras redes sociales en Facebook @buenosdiasam, Instagram buenosdiasamericaam o escríbenos a nfoudradio@UNIVISION.NET estaríamos encantados de recibirlas.

Research recently published in the medical journal "The Lancet" says that non-infectious health conditions such as high blood pressure are on the rise in Nepal. Led by public health expert Rajshree Thapa, the report finds that a 12-month intervention program carried out by female community health volunteers has not been sustainable. Thapa, who is a Postdoctoral Research fellow at Melbourne's Monash University says communities in Nepal need effective education and monitoring in terms of regular health checkups. She spoke to SBS Nepali about her research, the public health conditions in Nepal, and life as an international student in Australia. - नेपालमा महिला स्वयंसेविकाहरूले ‘ब्लड प्रेसर' नाप्ने र ‘लाइफस्टाइल चेन्ज' सम्बन्धी कार्यक्रमहरू गर्दै आएता पनि दीर्घकालीन रूपमा ती प्रभावकारी नरहेको बताइएको छ। जनस्वास्थ्य विज्ञ राजश्री थापाको नेतृत्वमा चार वर्षको अन्तराल पछि गरिएको अध्ययनले स्वयंसेविकाहरूद्वारा सम्पन्न एक १२-महिने कार्यक्रम खासै प्रभावकारी नरहेको पत्ता लगाएको हो। हाल मेलबर्न स्थित मोनास युनिभर्सिटीमा पोस्ट डक्टरल रिसर्च फेलो रहेकी थापा सहितको एक समूहले गरेको उक्त अध्ययनको नतिजा “दि ल्यान्सेट” नामक एक मेडिकल जर्नलमा केही दिन अघि मात्रै प्रकाशित भएको थियो। थापा भन्छिन् कि स्वस्थ रहन नेपालीहरूलाई यसबारे नियमित रूपमा जनचेतना फैलिने खालको शिक्षा र अनुगमन आवश्यक हुन सक्छ। अस्ट्रेलियामा आफ्नो अध्ययन, अनुसन्धान, बसोबास लगायत नेपालमा जनस्वास्थ्यको स्थिति सम्बन्धी विविध विषयहरू बारे उनीसँग एसबीएस नेपालीले गरेको कुराकानी सुन्नुहोस्।

This may be a touchy subject but it's one that deserves serious discussion. Brandon Smith wonders, why American churches are eerily silent when the country needs them the most. It's not uncommon to hear the term "dead end job" used to refer to entry-level work. Art Carden has a thoughtful essay on why America needs more "McJobs." We all know individuals who are currently dealing with pain, loneliness and sorrow. Jon Miltimore shares a favorite literary passage that helps put things into perspective. Not to pick open an old wound but would it surprise you to learn that a study by the British medical journal Lancet disappeared within 24 hours? Specifically, it was a study that purports to show that a high number of deaths could be attributed to reactions to the covid vaccine. Interesting. What happens to societies that surrender their moral foundation? Allen Mashburn says, we don't have to guess. Historically, these societies self-destruct. Sponsors: Monticello College Life Saving Food  TMCP Nation Climbing Upward

This may be a touchy subject but it's one that deserves serious discussion. Brandon Smith wonders, why American churches are eerily silent when the country needs them the most. It's not uncommon to hear the term "dead end job" used to refer to entry-level work. Art Carden has a thoughtful essay on why America needs more "McJobs." We all know individuals who are currently dealing with pain, loneliness and sorrow. Jon Miltimore shares a favorite literary passage that helps put things into perspective. Not to pick open an old wound but would it surprise you to learn that a study by the British medical journal Lancet disappeared within 24 hours? Specifically, it was a study that purports to show that a high number of deaths could be attributed to reactions to the covid vaccine. Interesting. What happens to societies that surrender their moral foundation? Allen Mashburn says, we don't have to guess. Historically, these societies self-destruct. Sponsors: Monticello College Life Saving Food  TMCP Nation Climbing Upward --- Support this podcast: https://podcasters.spotify.com/pod/show/loving-liberty/support

Anya Sharman, Assistant Editor at The Lancet, is joined by Pat McGorry and Stephan Zipfel to discuss breaking down barriers in mental health services, specifically, the challenges that professionals face when working in mental health, their role in scaling-up services, and the stigma surrounding the profession. You can see all of our Spotlight content relating to mental health here:https://www.thelancet.com/lancet-200/mental-health?dgcid=buzzsprout_tlv_podcast_lancet200_uhcFind out more about how The Lancet is marking its 200th anniversary with a series of important spotlights here:https://www.thelancet.com/lancet-200?dgcid=buzzsprout_tlv_podcast_lancet200_uhc

Friendships don't just happen; they take nurturing to grow and deepen.  This episode is dedicated to friendships and the meaningful ways friends make our lives better. In this episode, the Surgeon General is joined by his two pals Sunny and Dave. Together, they have what's called a moai.  Moais are a friendship tradition from Okinawa, Japan – essentially, it is a friend circle that starts in childhood. Moais offer emotional and moral support, and the effect on people's health can be remarkably positive. In Okinawa, an island known for some of the longest life expectancy in the world, some moais have lasted for over 90 years!  This episode is an invitation to a unique and deeply personal space, as Dr. Murthy and his friends talk about the power of being seen and valued for who you are.   We hope this episode inspires you to build and strengthen connections in your life. Please share with others who are seeking the same.   (05:45)   What is a Moai?  (10:51)   How did their Moai begin?  (17:39)   How has the Moai made a difference in their lives?  (32:06)   How has being in the Moai impacted their families?  (36:27)   The power of an explicit friendship commitment  (45:16)    What exactly are we chasing in life?  (48:02)    How can you start your own Moai?  Dr. Sandeep (Sunny) Kishore, Physician-Scientist Twitter: ⁠@sandeep_kishore⁠  Instagram: ⁠@sunnyk5⁠  Dr. Dave Chokshi, Physician & Public Health Leader  Twitter: @davechokshi    About Dr. Sunny Kishore & Dr. Dave Chokshi Dr. Sandeep (Sunny) Kishore is a physician-scientist at the University of California, San Francisco. He has worked on closing the “know-do” gap and translating scientific insights into real-world applications with focus on chronic disease prevention & control. Currently, he is focused on developing a scalable treatment algorithm for blood pressure control to improve cardiometabolic health for primary care clinics across the University of California. His work has led to the addition of over ten treatments to the Essential Medicines List of the World Health Organization (WHO) for cardiovascular disease, cancer, diabetes and mental illness. He also has provided technical guidance to Resolve to Save Lives with a focus on fixed dose combinations for blood pressure and led large global networks focused on reducing the toll of chronic illness worldwide.   Dr. Kishore has delivered remarks for United Nations General Assembly health sessions, WHO, TEDMED and his work has been featured in JAMA, The Lancet, Bulletin of WHO and Scientific American. He is a fellow of the New York Academy of Medicine, an Emerging Leader for the National Academy of Medicine and is a recipient of the Paul & Daisy Soros Fellowship for New Americans. He received the Raymond W. Sarber Award for top American graduate student in microbiology for doctoral research on anti-malarial strategies. He completed his medical and graduate training at Weill Cornell/Rockefeller/Sloan-Kettering Institute and Oxford, undertook his clinical training at Yale and Brigham & Women's Hospital/Harvard Medical School and has held fellowships at Harvard, Yale and the Dalai Lama Center at MIT. He currently resides in the Bay Area with his wife. Dr. Dave A. Chokshi is a practicing physician and public health leader who most recently served as the 43rd Health Commissioner of New York City. From 2020-2022, he led the City's response to the COVID-19 pandemic, including its historic campaign to vaccinate over 6 million New Yorkers. Previously, Dr. Chokshi was the inaugural Chief Population Health Officer at the largest public healthcare system in the nation. He has held successive senior leadership roles that span the public, private, and nonprofit sectors. A Rhodes Scholar and White House Fellow, he is nationally recognized as a transformational leader, a clinical innovator, a policy expert, and a fierce advocate for a stronger and more equitable health system.